Tocilizumab是一种人源化中和抗体，靶向人白细胞介素-6受体（IL-6R）。通过阻断IL-6与IL-6R的结合，有效抑制IL-6介导的经典信号通路与反式信号传导，应用于类风湿性关节炎的相关研究，在重症COVID-19的治疗研究中显示出显著疗效。

Purity

Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

SEC-HPLC

The purity of Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) is 97.55%, determined by SEC-HPLC.

ELISA

Immobilized FcRn (FCGRT) His+FcRn (B2M) at 2 μg/mL can bind Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab), EC50=0.0103 μg/mL.

-25~-15℃保存，有效期1年。